Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs PHENYTOIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Phenytoin is a hydantoin anticonvulsant that stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. It use-dependently blocks voltage-gated sodium channels, prolonging their inactivation phase and reducing high-frequency repetitive firing of action potentials.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Generalized tonic-clonic seizures (grand mal epilepsy),Complex partial seizures (psychomotor/temporal lobe seizures),Prevention and treatment of seizures occurring during or following neurosurgery,Status epilepticus (intravenous formulation)
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
Oral: 300-400 mg/day in 3-4 divided doses; IV: 15-20 mg/kg loading dose, then 300 mg/day maintenance.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Average terminal half-life 22 hours (range 7–42 hours) in adults; dose-dependent due to saturation of metabolism at therapeutic concentrations (10–20 mg/L). Half-life increases with higher doses.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Phenytoin is extensively metabolized in the liver primarily by the cytochrome P450 enzyme CYP2C9, with minor contributions from CYP2C19. The major metabolite is the glucuronide conjugate of 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH). Phenytoin exhibits dose-dependent, saturable (Michaelis-Menten) pharmacokinetics.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Primarily hepatic metabolism (>95%); less than 5% excreted unchanged in urine. Renal excretion of metabolites (glucuronides) accounts for ~80% of elimination; biliary/fecal excretion of metabolites ~20%.
38-45%, primarily bound to albumin.
90–95% bound, primarily to albumin; binding is saturable and decreases in hypoalbuminemia, uremia, or with other highly bound drugs.
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
0.6–0.8 L/kg; indicates extensive tissue distribution; crosses blood-brain barrier; Vd increases in neonates and decreases in renal failure.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral: 90–100% (phenytoin sodium extended-release); IM: low and erratic (not recommended) due to precipitation and slow absorption.
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
No specific GFR-based adjustment required; use with caution in severe renal impairment (GFR < 10 m L/min) due to protein binding changes.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 25-50%; Child-Pugh C: Reduce dose by 50-75%.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Loading dose: 15-20 mg/kg IV/PO; Maintenance: 5-10 mg/kg/day PO in 2-3 divided doses.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
Start at low end of dosing range (e.g., 3 mg/kg/day); monitor for toxicity; consider reduced protein binding and slower metabolism.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
Intravenous administration of phenytoin is associated with serious cardiovascular adverse reactions including severe hypotension and cardiac arrhythmias (e.g., bradycardia, heart block, ventricular fibrillation). These reactions can occur more frequently in patients with advanced age, known cardiac disease, or those receiving other medications that affect the cardiovascular system. Continuous monitoring of ECG and vital signs is required during IV administration, and the rate of infusion should not exceed 50 mg/min in adults.
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Cardiovascular risk during IV administration (see black box warning),Hypersensitivity reactions: Angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS),Hepatic injury: Acute hepatotoxicity, including elevated liver enzymes and hepatitis,Hematologic effects: Agranulocytosis, thrombocytopenia, leukopenia, pancytopenia,Central nervous system effects: Nystagmus, ataxia, slurred speech, mental confusion, dizziness, drowsiness,Hyperglycemia: May elevate blood glucose levels,Osteomalacia and hypocalcemia due to altered vitamin D metabolism,Teratogenicity: Fetal hydantoin syndrome (craniofacial abnormalities, growth deficiency, intellectual disability),Birth defects: Increased risk of cardiovascular malformations and neural tube defects,Carcinogenicity: Long-term use associated with increased risk of malignancies (lymphoma, hepatocellular carcinoma)
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to phenytoin, other hydantoins, or any component of the formulation,Sinus bradycardia, sinoatrial block, second- or third-degree AV block, Adams-Stokes syndrome,Concurrent use with delavirdine (due to decreased delavirdine concentrations),History of prior acute hepatotoxicity attributable to phenytoin,Porphyria (may precipitate acute attacks)
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
Enteral tube feedings can decrease phenytoin absorption; hold feeds 1-2 hours before and after administration. High-fat meals may increase absorption consistency. Folic acid supplementation may lower phenytoin levels. Calcium supplements and antacids can impair absorption; separate by 2-3 hours.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
Phenytoin is associated with fetal hydantoin syndrome, including craniofacial dysmorphisms, cardiac defects, neural tube defects, and cognitive impairment. Risk is highest during first trimester (organogenesis). Second and third trimester exposure may cause impaired fetal growth, microcephaly, and neurodevelopmental delay. Risk of major malformations is dose-dependent and increases with polytherapy.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Phenytoin is excreted into breast milk with estimated infant dose of 2-10% of maternal weight-adjusted dose; M/P ratio approximately 0.18-0.45. Generally considered compatible with breastfeeding; monitor infant for drowsiness, poor feeding, and rash. Avoid if maternal dose >400 mg/day or signs of infant toxicity.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
Pregnancy decreases phenytoin concentrations due to increased clearance (hepatic induction, increased Vd, decreased albumin). Dose adjustments are frequently required: increase total daily dose by 30-50% on average, guided by free phenytoin concentrations (target 1-2 mcg/m L). Monitor serum levels every 2-4 weeks, especially in third trimester. Postpartum, dose should be reduced to prepregnancy levels over 1-2 weeks to avoid toxicity.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
Phenytoin exhibits zero-order kinetics at therapeutic levels; small dose increases can cause toxicity. Monitor free phenytoin levels in hypoalbuminemia or uremia. Fosphenytoin is a prodrug used for IV loading with fewer infusion-site reactions. Caution in CYP2C9 poor metabolizers; consider genetic testing. May cause folate deficiency, peripheral neuropathy, and osteomalacia with long-term use. Co-administration with valproate displaces phenytoin from protein binding, increasing free fraction.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take exactly as prescribed; do not skip doses or change brands without consulting your doctor.,Do not stop taking suddenly as this may cause withdrawal seizures.,Avoid alcohol as it can affect drug levels and increase side effects.,Report any rash, fever, swollen glands, or mouth sores immediately (risk of Stevens-Johnson syndrome).,Use reliable contraception if sexually active; phenytoin reduces effectiveness of hormonal contraceptives.,Maintain good dental hygiene and see dentist regularly; may cause gum overgrowth.,Take with food if stomach upset occurs, but avoid high-fat meals if consistent timing is needed.,May cause dizziness, drowsiness, or blurred vision; avoid driving until you know how it affects you.
No interactions on record
"Coadministration of phenytoin and dexbrompheniramine may increase the risk of central nervous system (CNS) depression, leading to excessive sedation, dizziness, and impaired psychomotor function. Phenytoin, a sodium channel blocker used for seizure control, and dexbrompheniramine, a first-generation antihistamine with strong anticholinergic and sedative properties, synergistically depress CNS activity. This interaction can result in additive sedation, potentially compromising patient safety, especially in activities requiring alertness."
"Phenytoin is a potent inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes. Dasatinib is primarily metabolized by CYP3A4. Coadministration with phenytoin significantly reduces dasatinib plasma concentrations, potentially leading to subtherapeutic levels, reduced efficacy, and increased risk of disease progression in chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia."
"Phenytoin, a known inducer of CYP450 enzymes (particularly CYP3A4 and CYP2C9), increases the hepatic metabolism of ambroxol, a mucolytic agent primarily metabolized via CYP3A4. This induction reduces ambroxol plasma concentrations, potentially diminishing its therapeutic efficacy in clearing respiratory secretions. Clinically, patients may experience reduced mucolytic effects, leading to inadequate clearance of bronchial secretions and worsening of underlying respiratory conditions."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs PHENYTOIN, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. PHENYTOIN is a Anticonvulsant that works by Phenytoin is a hydantoin anticonvulsant that stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. It use-dependently blocks voltage-gated sodium channels, prolonging their inactivation phase and reducing high-frequency repetitive firing of action potentials.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and PHENYTOIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of PHENYTOIN is: Oral: 300-400 mg/day in 3-4 divided doses; IV: 15-20 mg/kg loading dose, then 300 mg/day maintenance.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and PHENYTOIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. PHENYTOIN is classified as Category D/X. Phenytoin is associated with fetal hydantoin syndrome, including craniofacial dysmorphisms, cardiac defects, neural tube defects, and cognitive impairment. Risk is highest during f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.